ORIFARM A/S: Financial statements 2024
CVR: 26058708
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ORIFARM A/S (CVR 26058708) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 1,223,777,000 and a net result of DKK 14,865,000 compared with DKK 18,874,000 the year before. That is a decrease of 22.3% compared with the year before. The profit margin was 1.2%. Equity in the 2024 report amounted to DKK 53,921,000. The solvency ratio was 35.9%. The company had 37 employees in the financial year.
- Revenue
- DKK 1,223,777,000
- Gross Profit
- DKK 23,231,000
- Profit/Loss
- DKK 14,865,000
- Equity
- DKK 53,921,000
- Total Assets
- DKK 150,368,000
- Employees
- 37
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 1.2B | 23.2M | 14.9M | 53.9M | 37 |
| 2023 | 1.6B | 27.6M | 18.9M | 76.3M | 37 |
| 2022 | 1.4B | 20.2M | 9.9M | 57.4M | 34 |
| 2021 | 1.5B | 19.5M | 8.2M | 47.4M | 40 |
| 2020 | 1.2B | 35.4M | 6.6M | 42.3M | 42 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ORIFARM A/S has won the tender "Amgros 2025 1.542.b" issued by Amgros I/S worth 58,800,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.351.b" issued by Amgros I/S worth 22,702,680,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1163.a" issued by Amgros I/S worth 1,644,000,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1211.b" issued by Amgros I/S worth 14,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.709.a" issued by Amgros I/S worth 145,756,745 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1208.b" issued by Amgros I/S worth 7,330,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 2.212.a" issued by Amgros I/S worth 14,666,754 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.205.a" issued by Amgros I/S worth 37,203,010 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.162.a" issued by Amgros I/S worth 1,526,400,000 DKK.
ORIFARM A/S has won the tender "Amgros 2025 1.1402.a" issued by Amgros I/S worth 1,090,000 DKK.
About ORIFARM A/S
ORIFARM A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2001. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named JUT NR. 2181 A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM PI A/S. The company has 39 employees (2026). In 2025, the company reported revenue of DKK 1,174,659,000 and a net result of DKK 9,727,000 compared with DKK 14,865,000 the year before. Equity in the 2025 report amounted to DKK 44,048,000.